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Abstract 
Clinical use of adipose-derived stem cells (ASCs) for a variety of indications is rapidly expanding in medicine. Most 
commonly, ASCs are isolated at the point of care from lipoaspirate tissue as the stromal vascular fraction (SVF). The 
cells are immediately administered to the patient as an injection or used to enrich fat grafts. Isolation of ASCs from 
adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point 
of care for immediate clinical administration requires special methodology to prevent contamination, ensure integrity 
of clinical research and comply with regulatory requirements. A lack of practical laboratory experience, regulatory 
uncertainty and a relative paucity of objective published data can make selection of the optimum separation method 
for specific indications a difficult task for the clinician and can discourage clinical adoption. In this paper, we discuss 
the processes which can be used to separate SVF cells from fat tissue. We compare the various mechanical and enzy-
matic methods. We discuss the practical considerations involved in selecting an appropriate method from a clinical 
perspective. Studies consistently show that breakdown of the extracellular matrix achieved with proteolytic enzymes 
affords significantly greater efficiency to the separation process. SVF isolated through mechanical methods is equally 
safe, less costly and less time consuming but the product contains a higher frequency of blood mononuclear cells 
and fewer progenitor cells. Mechanical methods can provide a low cost, rapid and simple alternative to enzymatic 
isolation methods, and are attractive when smaller quantities of ASCs are sufficient.
© 2015 Aronowitz et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
The clinical use of autologous adipose-derived stem cells 
(ASCs) is rapidly expanding because of promising results 
across a wide range of conditions. While progress in the 
use of cultured, modified and induced pluripotential cells 
has been measured in laboratory milestones, the use of 
autologous adipose-derived pluripotent cells is burgeon-
ing at the clinical level. Clinical and pre-clinical studies 
show that autogenous ASCs demonstrably survive after 
transplantation, show pluripotential differentiation (Zuk 
et al. 2001; Planat-Benard et al. 2004; Naderi et al. 2014; 
Ude et  al. 2014) and exhibit anti-apoptotic, anti-inflam-
matory, and angiogenic effects (Rehmam et  al. 2004; 
Kapur and Katz 2013; Suga et  al. 2010; Eto et  al. 2012; 
Kato et al. 2014).
Applications as diverse as myocardial infarction, cos-
metic surgery, osteoarthritis and bone regeneration, 
inflammatory bowel disease and chronic wounds are 
reported among a myriad of others (Savi et al. 2015; Mat-
sumoto et  al. 2006; Di Rocco et  al. 2010; Asatrian et  al. 
2015; Nagaishi et  al. 2015). There is some variation in 
the number of stem cells present in various donor sites 
and with donor age (Jurgens et  al. 2008; Vilaboa et  al. 
2014; Buschmann et al. 2013). In general, the most effi-
cient methods can isolate about 500,000–1,000,000 cells 
per gram of lipoaspirate tissue with a >80  % viability. 
The number of viable cells required for treatment of a 
particular condition is unknown because there is insuf-
ficient data to establish a reliable dose vs effect relation-
ship. In general, because no additional adverse effects are 
reported with the use of autologous ASCs in fat grafting, 
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the largest number of cells isolated at the point of care 
without expansion in culture is typically used. Despite a 
lack of reported clinical risk, in vitro studies have dem-
onstrated potential oncological risks which clinicians 
should be cautious of when using SVF based therapies 
(Bertolini et al. 2012; Bielli et al. 2014).
The surge in clinical applications for ASCs increases 
the need for clear and reliable information about the 
efficiency, cost and safety of automated equipment and 
manual techniques which facilitate separation of the 
stromal vascular fraction (SVF) from adipose tissue. In 
clinical practice, adipose-derived stem cells are often not 
administered as a pure isolate but rather as one constitu-
ent of stromal vascular fraction, a heterogeneous mix-
ture of cells resulting from the mechanical or enzymatic 
processing of aspirated adipose tissue. SVF contains a 
variety of cells including macrophages, various blood 
cells, pericytes, fibroblasts, smooth muscle cells, vascu-
lar endothelial progenitors and adipose-derived stem 
cells (Yoshimura et al. 2006; Bourin et al. 2013; Han et al. 
2010; McIntosh et al. 2006; Bonab et al. 2006; Yoshimura 
et al. 2009). Stromal vascular fraction is one component 
of the heterogeneous mixture of adipose tissue frag-
ments, stromal tissue, blood and tumescent fluid which 
constitutes lipoaspirate. The ASC content of SVF varies 
substantially depending on the method employed, with 
reports from less than 1 % of cells to over 15 % (Table 1). 
SVF cells can be safely isolated, quantified and character-
ized at the point of care in approximately 90  min. This 
is a timeframe which permits isolation and treatment to 
occur in the same surgical procedure, that is, at the point 
of care (POC).
Enzymatic methods
Enzymatic methods of isolating SVF cells from adipose 
tissue at the POC are based on a commonly used labora-
tory method of obtaining stem cells. The methods used to 
manually process adipose tissue using collagenase follow 
the same basic steps, but vary slightly in technique and 
reagents used. Lipoaspirate is washed 2–3 times using 
an aqueous salt solution such as PBS, Lactated Ringer’s 
solution, or Hank’s Balanced Salt Solution (HBSS). The 
washed lipoaspirate is then incubated with a collagenase 
solution of variable concentration and composition, 
depending on the method and tissue dissociation enzyme 
product used. Enzymatic digestion is typically carried out 
in a heated shaker to provide constant agitation at 37 °C 
for 30 min to 2 h. The digested adipose tissue is then cen-
trifuged (speed/duration vary. See Table  1) which sepa-
rates the processed lipoaspirate into three main layers, 
the oil/adipose tissue layer, the aqueous layer, and the pel-
let. The SVF is contained within the pellet, so the other 
layers are discarded, although SVF cells can be recovered 
from the aqueous layer (Yoshimura et al. 2006). The pel-
let is washed to remove any residual enzyme and filtered 
to remove tissue fragments and detritus. Collagenase-
based enzymatic methods can be up to 1000 times more 
effective in SVF cell recovery than mechanical methods. 
Enzymatic methods are more efficient in isolating SVF 
cells because disruption of the collagen-based extracel-
lular matrix (ECM) which binds together adipocytes and 
other cells of adipose tissue.
Tissue dissociation enzyme mixtures used for the sep-
aration process are usually a mixture of type I and type 
II collagenases isolated from Clostridium histolyticum, 
and various other proteolytic enzymes such as neutral 
protease (Dispase) (Fogarty and Griffin 1973; Griffin and 
Fogarty 1973) isolated from P. polymyxa or thermolysin 
(Ke et  al. 2013) isolated from G. stearothermophilus or 
B. thermoproteolyticus, depending on the product used. 
Commonly enzymatic methods are carried out using 
tissue dissociation enzyme mixtures such as CIzyme™ 
AS (Vitacyte LLC, Indianapolis, Indiana) or Liberase™ 
Research Grade (Roche Diagnostics, Basel, Switzerland). 
CIzyme™ AS is a mixture of type I and type II clostridial 
collagenase and dispase. The Liberase™ Research Grade 
enzyme mixture recommended for adipose-tissue diges-
tion is mixture of type I and type II clostridial collagenase 
and thermolysin. Mixtures of enzymes have been shown 
to yield more nucleated cells than using only one enzyme, 
a quality attributed to the synergistic effect of the proteo-
lytic enzymes in the breakdown of the ECM (McCarthy 
et al. 2010, 2011; Breite et al. 2010); however collagenase 
is still frequently used as the sole proteolytic enzyme 
in methods using products such as Collagenase NB6 
(SERVA Electrophoresis GmbH, Heidelberg, Germany) 
or Collagenase type I CLS 270 (Worthington Biochemi-
cal Corporation, Lakewood, NJ).
Published yields of viable, nucleated SVF cells achieved 
using manual, collagenase-based digestions range from 
100,000 nucleated cells/cc to 1,300,000 nucleated cells/
cc of lipoaspirate processed (Table 1). Equipment like the 
PNC Multi-Station (PNC International, Gyeonggi-do, 
Republic of Korea) is commercially available for use in 
the manual preparation of SVF. The PNC Multi-Station 
contains a centrifuge and heated shaker inside of a ster-
ile biohood which allows the entire processing to be con-
ducted in sterile conditions.
Mechanical isolation methods
Mechanical methods for SVF isolation report signifi-
cantly lower yields of nucleated cells/cc of lipoaspirate 
processed. Cell yields are reported from 10,000 nucle-
ated cells/cc of lipoaspirate to 240,000 nucleated cells/
cc of lipoaspirate (Table  1). Mechanical methods seek 
alternative non-enzymatic means of removing SVF cells 
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from the adipose tissue and tend to be focused around 
washing and shaking/vibrating lipoaspirate followed by 
centrifugation in order to concentrate the SVF cells. All 
of the mechanical methods mentioned in this article con-
tain a centrifugation step in order to concentrate the SVF 
cells. The composition of the cell populations recovered 
through simple centrifugation and other non-enzymatic 
methods have been shown to contain a greater frequency 
of peripheral blood mononuclear cells and a substan-
tially lower number of progenitor cells (Conde-Green 
et al. 2014; Raposio et al. 2014; Shah et al. 2013). This is 
because ASCs are concentrated in the small and medium 
sized vascular structures of adipose tissue, and without 
enzymatic lysis of the collagen-based extracellular matrix 
many progenitor cells remain trapped within the vascular 
endothelium layers and connective tissue fragments in 
the lipoaspirate.
While enzymatic methods consistently yield higher 
cell counts with a higher frequency of progenitor cells, 
mechanical methods do offer some distinct advantages. 
The digestion of adipose tissue to disperse the cellu-
lar constituents prolongs the isolation time and can be 
fairly expensive, with costs of $2–$5 per gram of tissue 
processed using GMP grade enzymes (Aronowitz and 
Ellenhorn 2013). In settings where maximum numbers 
of progenitor cells are not critical, a non-enzymatic sep-
aration method like that of Raposio et  al. can provide a 
cost-effective alternative (Raposio et al. 2014). Addition-
ally, mechanical methods tend to offer a faster processing 
time, some less than 15 min, because they do not require 
the extra 30–120 min allotted for enzymatic digestion to 
occur.
Mechanical vs enzymatic methods
In 2014, Raposio et al. reported a non-enzymatic method 
for SVF isolation (Raposio et  al. 2014). This method 
involves shaking lipoaspirate in a vibrating shaker for 
6  min at 600 vibrations per minute and then centrifug-
ing at 1600 rpm for 6 min to isolate the SVF cells. Rapo-
sio et  al. reported that they were able to isolate around 
125,000 nucleated cells per cc of lipoaspirate processed, 
however only about 5  % of these cells were progenitor 
cells, with the other 95 % being predominantly blood cells 
and endothelial cells. In comparison, enzymatic meth-
ods have reported SVF yields with significantly higher 
numbers of progenitor cells, for example one automated 
collagenase-based isolation system which was shown 
to yield over 15 % progenitor cells in the SVF (Aronow-
itz and Ellenhorn 2013). The discrepancy in SVF com-
position was supported by the paper by Conde-Green 
et  al. (2014). Conde-Green et  al. compared a standard 
collagenase-based method to two different mechanical 
methods. They reported that both mechanical methods 
yielded SVF populations with lower nucleated cell counts 
and lower frequencies of progenitor cells than the man-
ual, enzymatic approach examined.
In 2014, Markarian et  al. compared a variety of pro-
cessing methods for SVF isolation side by side, both 
enzymatic and mechanical. Collagenase-based diges-
tion was shown to be the most effective in terms of cell 
recovery Markarian et  al. (2014). They reported about 
350,000 nucleated cells/cc of lipoaspirate processed using 
a collagenase-based method. Another method examined 
was a non-enzymatic method involving centrifugation 
of lipoaspirate at either 800 g or 1280 g. At both speeds 
tested, far fewer nucleated cells were isolated, with only 
about 10,000 nucleated cells recovered per cc of lipoaspi-
rate. They report no significant difference in viability 
between the various methods they examined.
In 2009, Baptista et  al. reported another manual, 
mechanical method (Baptista et al. 2009). In this method, 
lipoaspirate is incubated with red blood cell (RBC) lysis 
buffer (150  mM NH4Cl, 10  mM KHCO3, 1  mM EDTA) 
at 37  °C for 15  min and then centrifuged for 15  min at 
900g. They reported an average yield of about 240,000 
nucleated cells per cc of lipoaspirate processed, but only 
about 12,000 of these (5  %) were adipose-derived stem 
cells. This was supported by Shah et al. (2013). They com-
pared a similar method using PBS instead of RBC lysis 
buffer with the common collagenase-based method. Shah 
et  al. cultured samples from each method to determine 
ASC content. They reported that once samples reached 
80–90  % confluence that an average of 25,000 adipose-
derived stem cells per cc of lipoaspirate processed were 
found in the sample acquired using this mechanical 
method, but 480,000 adipose-derived stem cells per cc of 
lipoaspirate we found in the sample acquired using the 
enzymatic method. Additionally, Shah et al. observed that 
the cells acquired using collagenase proliferated much 
more quickly when cultured, requiring less than half the 
time to reach 80–90  % confluence (6  days vs 13  days). 
This method using RBC lysis buffer was also tested by 
Markarian et al. (2014). They however reported a much 
lower yield, only about 25,000 viable cells/cc lipoaspirate 
processed.
The differences resulting in the yields observed using 
mechanical and enzymatic methods can be partially 
attributed to the physical location of SVF cells in adi-
pose tissue. The SVF cells, particularly the mesenchy-
mal stem cells and pericytes, tend to be localized in the 
perivascular space (Baer and Geiger 2012). As demon-
strated by Zimmerlin et al. in 2010, immunohistochemi-
cal and immunofluorescent analysis reveal a localization 
of ASC and pericytes in these perivascular niches (Zim-
merlin et  al. 2010). Mechanical methods of isolation do 
not afford the same release of cells from the perivascular 
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spaces because the disruption of the extracellular matrix 
is significantly reduced compared to enzymatic methods, 
leaving many of the desired cells trapped in larger tissue 
fragments which are subsequently discarded. As a result, 
the composition of the SVF resulting from mechanical 
isolations tends to be deficient in CD34 expression. This 
relative CD34+ progenitor deficiency has been suggested 
as a contributing factor to longer culture times required 
to reach 80–90  % confluence, as demonstrated by Shah 
et al. (2013).
Automated/semi‑automated devices for SVF 
isolation
Due to increasing interest of SVF cells in the clinical 
setting, various fully automated and semi-automated 
devices for SVF cell isolation, both enzymatically and 
mechanically based, have been developed by companies 
hoping to capitalize on this relatively new cellular tech-
nology. These devices employ similar methods to manual 
enzymatic and mechanical methods, but under more 
controlled conditions. In efforts to improve the yield of 
SVF isolation, many companies have developed process-
ing systems which seek to optimize the isolation pro-
cess by reducing the human element and limiting loss 
of viability due to processing, while still adhering to the 
current Good Manufacturing Practices (cGMP) (FDA 
2014a). Some of these devices have been able to isolate 
large numbers of cells, while other devices have been 
shown to be less impressive. These companies continue 
to improve the devices and technology so as to opti-
mize the cellular recovery and viability. While many of 
the automated systems are currently too expensive for 
use in the lab setting, it is very possible that these auto-
mated systems could become a common item used to 
provide safe and effective cellular therapies to patients in 
the clinical setting. Many of these companies are actively 
pursuing clinical trials in order to clinically validate their 
devices and technologies while also providing cellular 
therapy to patients in need, like the upcoming STAR trial 
(Cytori Therapeutics 2015) for treatment of scleroderma 
by Cytori Therapeutics, Inc. which has received an IDE 
from the FDA and is currently enrolling patients as of 
August 2015.
These automated and semi-automated systems tend to 
be small self-contained systems which are able to carry 
out each step of the process with little or no interference 
from a technician. One of the main benefits offered by 
many of these systems is increased sterility through the 
use of a closed system. Once the lipoaspirate is added 
to the device, it remains in a sterile environment, unlike 
many manual methods. In some devices, such as the GID 
SVF platform (GID Europe, London, UK), the lipoaspi-
rate is harvested directly into the system (Vilaboa et  al. 
2014). These devices are all slightly different, but ulti-
mately seek to achieve the same goal.
The Cytori Celution system (Cytori Therapeutics, Inc., 
San Diego, CA) has been reported in multiple studies. 
The Celution system is a closed, fully automated system 
which employs Cytori’s proprietary enzyme blend, Cel-
ase. The Celution system is capable of processing up to 
360  cc of lipoaspirate at one time. The Celution system 
has been consistently reported to yield between 240,000–
360,000 nucleated cells/cc of lipoaspirate processed and 
84–93  % viability, while also yielding a large popula-
tion of progenitors (Table  1) (Aronowitz and Ellenhorn 
2013; Lin et  al. 2008; Fraser et  al. 2013). The Celution 
system has been reported for use in a variety of clini-
cal applications including treatment of lower extremity 
ulcers, treatment of cryptoglandular fistulae, and breast 
augmentation (Marino et al. 2013; Borowski et al. 2015; 
Kakamura and Ito 2011). The Celution system possesses 
the CE mark, but is not commercially available in the 
United States; however, Cytori does have a number of 
Investigational Drug Exemptions (IDE) for trials using its 
ADRC technology though. Cytori currently has five clini-
cal trials underway for indications including scleroderma, 
knee osteoarthritis, urinary incontinence and cutaneous 
thermal injury.
Another device which has been described in literature 
is the GID SVF platform mentioned above. The GID SVF 
platform offers a completely disposable, single use, closed 
system process using its proprietary enzyme mixture, 
GIDzyme-2 (GID Europe 2015). The device can process 
up to 350  cc of dry adipose at one time. Vilaboa et  al. 
(2014) reported that using the GID SVF platform they 
were able to isolate 719,000 nucleated cells/cc of lipoaspi-
rate with 83 % viability. No information is provided per-
taining to progenitor content or clinical applications. The 
GID SVF platform has received the CE mark for distribu-
tion in the European Economic Area (EEA).
A device also reporting high cellular yields is the Tis-
sue Genesis Icellator Cell Isolation system (Tissue Gen-
esis, Honolulu, HI). The Icellator system is an automated, 
closed system which uses the Tissue Genesis proprietary 
enzyme blend, Adipase (Tissue Genesis 2015). In 2013, 
Williams et  al. reported a staggering 7.1 million viable 
SVF cells/mL of canine adipose tissue with 78  % viabil-
ity processed using the Icellator system (Williams et  al. 
2013). Another study conducted by Doi et  al. (2013) 
reported a lower, but still impressive yield of 702,000 
nucleated cells/cc of lipoaspirate with 80.7  % viability. 
Doi et  al. compared the Icellator system to a manual 
collagenase-based method using 0.075  % collagenase 
to digest adipose tissue. They reported that using this 
manual method they were able to isolate 701,000 nucle-
ated cells/cc of lipoaspirate with 82.4  % viability. No 
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information is provided pertaining to progenitor content. 
The Icellator system has not been evaluated by the FDA 
for use in humans.
The Sepax Technology from BioSafe America (Biosafe 
Group, Lake Geneva, Switzerland) is an enzymatic, 
fully-automated, closed system. While marketed pri-
marily for cord blood, bone marrow, and peripheral 
blood processing (Biosafe America 2015), it has been 
reported for use with adipose tissue as well. Guven 
et al. (2012) reported a yield of 260,000 nucleated cells/
cc of lipoaspirate processed with around 14  % CFU-F, 
which they compared to a manual, enzymatic method 
which was able to isolate 160,000 nucleated cells/cc of 
lipoaspirate with around 11 % CFU-F. Over 90 % viabil-
ity was reported in both groups. The Sepax-2 system 
has received a CE mark, 510(k) approval from the FDA 
and approval from the SFDA in China for processing 
of cord blood, bone marrow, and peripheral blood, not 
adipose tissue.
The Lipokit (Medi-Kan Int., West Hollywood, CA) is 
another semi-automated, enzymatic system. The Lipokit 
is an all in one system for the harvest, processing and 
transplant of SVF which can be used with or without 
enzyme (LipoKit II infomation 2015). The Lipokit uses 
custom disposable centrifuge syringes for the processing 
and handling of lipoaspirate, primarily for fat grafting, 
but can be used for isolation of SVF cells as well. There 
are very few articles published using the Lipokit, and in 
these reports, results vary widely. A study by Wang et al. 
(2012), reported on the effects of using the Lipokit for 
cell-assisted lipotransfer procedures in 18 patients. They 
reported 41.67  % ASCs in the SVF, but no data on cell 
count or viability was able to be acquired from the article. 
This report was contradicted by Aronowitz et al. (2013), 
who reported a much lower ASC frequency (1.7 %) with 
a fairly low nucleated cell yield, only about 35,000 cells/
cc of lipoaspirate processed. The Lipokit platform has a 
CE mark as well as 510 (k) approval from the FDA in the 
United States as a graft preparation system, but not as an 
isolation system for SVF cells.
There are fewer mechanical, automated and semi-auto-
mated devices available for SVF cell isolation because 
most mechanical isolations can be conducted using 
standard laboratory equipment, so there is less of a need 
for an all in one device. Multiple companies advertise 
automated and semi-automated, mechanical systems, 
but many do not have published articles to attest to the 
yields of these devices. In addition, many of those which 
have been developed have been deemed to be ineffective 
in the clinical setting, such as the Fastem/Corios system 
recently described by Domenis et  al. (2015). Domenis 
compared three methods of SVF isolation and cell-
enhanced fat graft preparation. Overall, they concluded 
that the two enzymatic methods examined, the Lipokit 
and the Celution system, resulted in significantly more 
nucleated cells and clonogenic and multipotent progeni-
tor cells for fat graft enhancement, while the Fastem/
Corios system was unable to isolate adequate cells to sig-
nificantly enhance a fat graft. No numbers for nucleated 
cell count, viability, or progenitor cell content are clearly 
reported.
One mechanical, semi-automated device which has 
reported adequate yields is the StromaCell system 
(Microaire Aesthetics, Charlottesville, VA). The Stroma-
Cell system is a patented centrifuge canister which allows 
for lipoaspirate to be harvested directly into the canister 
and easy recovery of the SVF cells from the canister after 
centrifugation at 1000g for 10 min (MicroAire Aesthetics 
2013). In a 2014 study by Millan et al. (2014), collagenase 
based digestion was compared to mechanical isolation 
using the StromaCell device for SVF isolation. While 
isolating fewer cells than the standard collagenase-based 
method (368,000 cells/cc of lipoaspirate vs 140,000 cells/
cc of lipoaspirate), they did report similar compositions 
in terms of progenitor content when analyzed by flow 
cytometry.
The main drawback of many of these devices is the cost 
of operation. The closed, enzymatic systems can be very 
expensive, with some costing over $50,000 for the system. 
In addition to purchasing the device, many require sin-
gle-use disposable kits which can cost hundreds or thou-
sands of dollars for a single disposable kit in some cases. 
A mechanical system like the StromaCell offers the ben-
efit of a closed sterile system and tends to be more afford-
able, but does not provide the superior yield afforded by 
the enzymatic systems such as the Cytori Celution sys-
tem or the Tissue Genesis Icellator system. All of the sys-
tems mentioned here can be operated by a single trained 
technician at the point of care. The processing times vary 
between systems, with mechanical systems being in the 
15–30  min range and the enzymatic systems ranging 
from about 60–90 min depending on the amount of tis-
sue processed.
Regulatory concerns
Many of the mechanical methods were initially developed 
in an attempt to isolate a population of cells which could 
be considered “minimally manipulated,” which many 
believed would allow them to circumvent a large amount 
of regulatory oversight by the United States Food and 
Drug Administration (FDA) and other regulatory agen-
cies around the world. Enzymatic methods produce cell 
populations which the FDA considers to be “more than 
minimally manipulated,” causing them to be more heav-
ily regulated as a drug, while the non-enzymatic methods 
were thought to be considered “minimally manipulated” 
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due to the ambiguity of certain areas of previous regula-
tory documents. Recent non-binding draft guidances for 
industry from the FDA (2014b, c) which clarify the FDA’s 
stance on minimal manipulation and adipose tissue 
derived HCT/P’s seek to classify all methods of SVF iso-
lation, both enzymatic and mechanical, as yielding “more 
than minimally manipulated” cells, and thereby classify-
ing SVF as a drug.
Conclusion
Methods used to isolate of pluripotential mesenchy-
mal cells from adipose tissue at the point of care are of 
increasing importance in medicine as a large body of clin-
ical research shows promise for a burgeoning number of 
conditions. Mechanical techniques, such as simple wash-
ing or centrifugation of lipoaspirate are effective in iso-
lating ASCs. Mechanical methods are appealing because 
they are simple, quick and generally not associated with 
expensive equipment or disposables. While more expen-
sive than mechanical options, enzymatic methods for the 
isolation of stromal vascular fraction cells from adipose 
tissue yield more nucleated cells with a higher number 
of progenitor cells per volume of lipoaspirate processed, 
but overall viability tends to be unaffected by processing 
method. While mechanical methods may be cost-effec-
tive in the laboratory setting, enzymatic methods pro-
vide a superior SVF output for use in the clinical setting. 
The method that a certain lab or facility uses ultimately 
depends upon their needs and financial capabilities. Labs 
and clinics with insufficient funding to use enzymatic 
methods or automated/semi-automated devices still have 
the option of pursuing mechanical methods. There are 
differences in the number of adipose stem cells present 
in the various adipose tissue deposits of an individual and 
significant variation between individuals but adipose tis-
sue in general is a rich source of pluripotential mesenchy-
mal cells.
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